ConvictaFree beta

HOFSETH BIOCARE ASA

Sector unknown·HBC · Oslo Børs·Fiscal year to 31/12/2024

Diabetes careGeopolitical uncertaintyShipping and logistics

Exposure profile

Raw materials and inputsMacroTechnologyRegulationEnd marketsGeography
Raw materials and inputs not mentioned
Macro Geopolitical uncertainty, USD vs DKK/EUR, Other currencies, Interest rates
Technology Diabetes care
Regulation not mentioned
End markets Shipping and logistics
Geography Europe, United States, Asia and emerging markets

Derived from what the company itself writes. Empty directions mean the report doesn't mention themes of that type.

In their own words

Grouped by theme, from the management review in the annual report. A · The company itself is a verbatim quote, B · From the report is without a verified quote.

Agriculture and food production

End markets

Market

“In addition to targeting multiple segments within human nutrition, such as sports nutrition, supplements, and health foods, the Group also serves the pet and feed industries, further reducing reliance on any single market.”

Annual report 2024A · The company itself

Chains in: Grain and agricultural commodities mixed effect, Climate change and extreme weather weakens, Grocery retail and private label weakens

Aquaculture and fish feed

End markets

Market

“The Group operates solely in the production of marine ingredients, namely salmon oil (OmeGo®), hydrolyzed soluble protein (ProGo®), Calcium/ Collagen (CalGo® or NT-II™), and non- soluble protein (PetGo™), all of which are produced in the Midsund plant.”

Annual report 2024A · The company itself

Beer and beverages

End markets

Market

“In addition to targeting multiple segments within human nutrition, such as sports nutrition, supplements, and health foods, the Group also serves the pet and feed industries, further reducing reliance on any single market.”

Annual report 2024A · The company itself

Chains in: Grain and agricultural commodities strengthens, Consumer preference shifts mixed effect, Packaging weakens

Diabetes care

Technology

StrategyPositive impact: strengthens

“Hofseth BioCare enters 2025 with renewed determination to advance its sustainable business model and realize our vision of improving lives through science-led marine nutrition. Building on the strong foundations and strategic achievements of 2024, including robust market performance, significant R&D progress, and resilience in a complex global environment, we are confident in our ability to drive continued growth and innovation in both human and pet nutrition.”

Annual report 2024A · The company itself

Premium consumers

End markets

Market

“In addition to targeting multiple segments within human nutrition, such as sports nutrition, supplements, and health foods, the Group also serves the pet and feed industries, further reducing reliance on any single market.”

Annual report 2024A · The company itself

Chains in: Consumer spending strengthens

Shipping and logistics

End markets

StrategyPositive impact: strengthens

“The group intends to transport more goods by rail and boat if solutions for such transport can compete with road transport regarding speed and infrastructure.”

Annual report 2024A · The company itself

Chains in: Carbon tax and ETS prices weakens, Global trade volumes strengthens, Fuel strengthens

Geopolitical uncertainty

Macro

DriverNegative impact: weakens

“Recent geopolitical uncertainties, including ongoing wars and significant political changes observed in 2024 and anticipated into 2025, have added a layer of complexity to the global market environment. These developments can disrupt supply chains, alter regulatory landscapes, and affect consumer confidence, potentially leading to fluctuations in demand and pricing.”

Annual report 2024A · The company itself

Chains out: this strengthens Defence budgets, strengthens Energy security, strengthens Tariffs and trade policy, weakens Global trade volumes, strengthens Sea freight and freight rates, weakens Reconstruction of Ukraine

Other currencies

Macro

DriverNegative impact: weakens

“Hofseth BioCare conducts transactions in multiple currencies, primarily US dollars and Euros. Exchange rate fluctuations inherently affect both the cost of raw materials and the pricing of products sold internationally.”

Annual report 2024A · The company itself

USD vs DKK/EUR

Macro

DriverNegative impact: weakens

“Hofseth BioCare conducts transactions in multiple currencies, primarily US dollars and Euros. Exchange rate fluctuations inherently affect both the cost of raw materials and the pricing of products sold internationally.”

Annual report 2024A · The company itself

Chains out: this mixed effect United States

Interest rates

Macro

DriverMixed impact: mixed

“Interest rate risk (own financing, deposits) Changes in general interest rates can influence the cost of financing as well as the value of the Group’s assets.”

Annual report 2024A · The company itself

Chains in: Public debt and fiscal policy strengthens, Inflation strengthens
Chains out: this weakens Construction, weakens Real estate, weakens Wind power, weakens Housing market, weakens Office and commercial property, weakens Residential rental, weakens Residential construction

Asia and emerging markets

Geography

Geography

“With distributors operating in more than 60 countries, local market expertise is leveraged to tailor sales strategies across Europe, North America, and Asia.”

Annual report 2024A · The company itself

Europe

Geography

Geography

“With distributors operating in more than 60 countries, local market expertise is leveraged to tailor sales strategies across Europe, North America, and Asia.”

Annual report 2024A · The company itself

United States

Geography

Geography

“With distributors operating in more than 60 countries, local market expertise is leveraged to tailor sales strategies across Europe, North America, and Asia.”

Annual report 2024A · The company itself

Chains in: USD vs DKK/EUR mixed effect

Competitors mentioned in the report

No named competitors in the report.

Financial figures

Revenue
latest fiscal year
0.26 bn NOK
Revenue growth
vs. the year before, same method
34.6 %
EBITDA
reported by the company
N/A
Net debt
debt incl. leasing minus cash
0.15 bn NOK
Diluted EPS
per share
-0.3 NOK

Source: annual report (ESEF) A. See the report

Criteria

Profit✗
Growing✓
Healthy balance sheetN/A

Only the criteria that can be computed from financial statements on this page. The remaining criteria (such as price and dividend) need a share price and are in the analysis.

Figures are in the report's currency (NOK), not converted to DKK. Quotes are shown as the company's own words in the report's original language.

This page describes what the company itself writes. It isn't an assessment and isn't a recommendation. Run an analysis to see how the company connects to your view.